What is the most recent FDA action on file for Park Avenue Compounding?

September 23, 2025. Argus HQ ingests new FDA enforcement records daily.

Is this FDA enforcement data for Park Avenue Compounding official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has Park Avenue Compounding had?

Argus HQ has recorded 1 FDA events for Park Avenue Compounding: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Park Avenue Compounding?

The most recent FDA event Argus HQ has on file for Park Avenue Compounding is dated 2025-09-23, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

FDA Actions Against Park Avenue Compounding

Argus HQ has recorded 1 FDA events for Park Avenue Compounding: 0 warning letters, 0 recalls, 0 approvals, and 1 inspection 483 observations. These events span from 2025-09-23 to 2025-09-23. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	0
Form 483 inspection citations	1
Most recent action	September 23, 2025

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Park Avenue Compounding has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2025-09-23, Argus HQ recorded an FDA Form 483 inspection citation for Park Avenue Compounding, rated "high" severity in Argus HQ's classification: Park Avenue Compounding -- FDA 483: 7 observations (2025-09-23). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

What is the most recent FDA action on file for Park Avenue Compounding?: September 23, 2025. Argus HQ ingests new FDA enforcement records daily.
Is this FDA enforcement data for Park Avenue Compounding official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has Park Avenue Compounding had?: Argus HQ has recorded 1 FDA events for Park Avenue Compounding: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Park Avenue Compounding?: The most recent FDA event Argus HQ has on file for Park Avenue Compounding is dated 2025-09-23, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Park Avenue Compounding -- FDA 483: 7 observations (2025-09-23) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Actions Against Park Avenue Compounding. Digital Empire LLC. Retrieved from https://argushq.ai/company/park-avenue-compounding

MLA

"FDA Actions Against Park Avenue Compounding." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/company/park-avenue-compounding.

Chicago

Argus HQ Research. "FDA Actions Against Park Avenue Compounding." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/park-avenue-compounding.

BibTeX

@misc{argushq_argushq_ai_company_park_avenue_compounding_2025,
  title = {FDA Actions Against Park Avenue Compounding},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/park-avenue-compounding},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗